Prilenia and Ferrer Highlight Compelling New Evidence of Pridopidine’s Disease-Modifying Potential in Huntington’s Disease at the 2025 HSG Congress Prilenia Therapeutics B.V. and Ferrer have jointly announced the presentation of five new scientific posters at the 2025 Huntington Study Group…
Novo Nordisk to Acquire Akero Therapeutics to Strengthen MASH Pipeline with Phase 3 FGF21 Analogue Efruxifermin Novo Nordisk, a global healthcare leader in diabetes and obesity treatments, has announced a definitive agreement to acquire Akero Therapeutics, Inc., a publicly traded,…
Eikonizo Therapeutics Highlights Breakthrough Preclinical Findings Demonstrating the Disease-Modifying Potential of Selective HDAC6 Inhibitors in ALS and FTD Eikonizo Therapeutics, a biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative and cardiorenal diseases, has announced the advance online publication of…
Aarvik Therapeutics Secures Strategic Investment from Laurus Labs in Series Seed 2 Financing Round Aarvik Therapeutics, a pioneering biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for cancer therapy, today announced a strategic investment by Laurus Labs, India, as…
Celltrion Showcases Real-World Evidence Supporting Switch from IV to Subcutaneous Infliximab at UEG Week 2025 Celltrion, Inc., a global leader in biopharmaceutical innovation, today highlighted compelling real-world evidence supporting the use of subcutaneous (SC) infliximab for patients with inflammatory bowel…
KalVista Pharmaceuticals Highlights EKTERLY® (Sebetralstat) as a Transformative Oral On-Demand Therapy for Hereditary Angioedema in Europe KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical-stage biotechnology company focused on developing innovative therapies for hereditary angioedema (HAE) and related disorders, today unveiled compelling…
Sonoma Biotherapeutics Co-Founder Fred Ramsdell Awarded 2025 Nobel Prize in Physiology or Medicine for Pioneering FOXP3 Discovery and Advancing Treg Immunotherapy Sonoma Biotherapeutics, Inc., a leading clinical-stage biotechnology company focused on developing engineered regulatory T cell (Treg) therapies for autoimmune…
Ignota Labs Strengthens Clinical Portfolio Through Acquisition of Kronos’s Development-Stage Assets Ignota Labs, an emerging pioneer in artificial intelligence–driven drug redevelopment, has announced the strategic acquisition of Kronos’s former clinical assets—istisociclib, a cyclin-dependent kinase 9 (CDK9) inhibitor, and entospletinib and…
Automated Cell Processing System Market Forecasts Set for Robust Growth Through 2035 Amid Rising Demand for Cell Therapies Automated Cell Processing System Market Industry Trends and Global Forecasts to 2035: Distribution by Cell Therapy Processing Step, Scale of Operation, End…
BUILT Biotechnologies Named Anchor Company at Commonwealth BioAccelerator, Scaling DNA Manufacturing-as-a-Service to Meet Surging Demand BUILT Biotechnologies,a rapidly emerging leader in DNA Manufacturing-as-a-Service, has announced its selection as an anchor company at the Commonwealth BioAccelerator, an initiative spearheaded by CvilleBioHub…
Global Molecular Diagnostics Market Set to Reach $30.9 Billion by 2035: Industry Trends, Technologies, and Key Players Molecular Diagnostics Market Industry Trends and Global Forecasts to 2035: Distribution by Test Type, Type of Offering, Type of Sample, Type of Technology,…
Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares Alpha Cognition Inc. (Nasdaq: ACOG) (the “Company”), a commercial-stage biopharmaceutical company committed to advancing innovative therapies for neurodegenerative diseases, today announced the pricing of its oversubscribed…